Practitioner education. Patient details are anonymized and may be composites.
A patient came into a three-month follow-up convinced a peptide deserved all the credit for his clearer head.
Then, almost as an afterthought, he mentioned that he had quit drinking, started sleeping seven hours a night, left a job he hated, and changed several other daily habits.
I wrote everything on the chart.
He only wanted to talk about one thing: the peptide.
That is where the reasoning can go wrong.
When a patient changes six variables at once, it is impossible to confidently assign the outcome to one intervention. The peptide may have contributed. It may not have. The honest answer is that the variables have not been separated.
Why Patients Often Credit the Peptide First
Picture a rooster.
It crows. The sun comes up. The rooster takes a bow.
It does this every morning.
But the rooster did not cause the sunrise. It simply happened before it.
The same mistake happens in clinical conversations. A patient feels better after starting a peptide and assumes the peptide caused the improvement. Meanwhile, sleep improved, alcohol intake dropped, stress decreased, movement increased, or another medication changed.
The peptide gets the credit because it is the most interesting variable.
Interesting does not mean causal.
Brain Fog Has More Than One Possible Cause
For complaints such as brain fog, poor focus, or reduced mental stamina, the first step should be identifying everything that changed. That includes:
- Sleep duration and quality
- Alcohol and other substances
- Stress and workload
- Physical activity
- Diet and energy balance
- Medications and supplements
- Thyroid status and relevant lab work
- B12 and other possible contributors
A patient with new or worsening cognitive symptoms needs an appropriate medical evaluation before assuming the answer is a peptide. The FDA notes that products intended to diagnose, treat, cure, or prevent disease are regulated as drugs, and that unapproved drugs have not been reviewed by FDA for safety, effectiveness, or quality [1, 2].
Where Semax, Selank, and Pinealon Fit
Some practitioners and patients ask about compounds such as Semax, Selank, and Pinealon when focus, stress, aging, or sleep are part of the conversation.
The important distinction is this:
These compounds may be discussed in the research literature, but that does not make them FDA-approved treatments or established solutions for brain fog.
Semax and Focus
Semax has been studied primarily in Russian research settings. Some publications describe potential neuroprotective or cognitive effects, including preclinical work involving ischemia and memory-related outcomes. However, animal findings do not establish clinical effectiveness in humans [3].
The FDA has raised concerns regarding Semax, including limited safety information, insufficient evidence of effectiveness for proposed uses, product characterization, and potential immunogenicity risks [4].
Selank and Stress-Related Fog
Selank has also been studied in Russian clinical research. One randomized study compared Selank with medazepam in patients with generalized anxiety disorder and neurasthenia [5]. Another clinical trial compared Selank with phenazepam in anxiety-related disorders [6]. These studies are worth knowing about, but they are not equivalent to large, modern, independently replicated trials establishing broad use for cognitive complaints.
The FDA has also identified limited safety information and potential risks involving compounded Selank acetate, including immunogenicity and peptide-related impurities [7].
Pinealon, Sleep, and Aging
Pinealon is often discussed in relation to aging, sleep, and neurocognitive health. But the evidence base is limited, and the absence of a completed, high-quality randomized human trial should materially affect how confidently it is presented [8, 9].
The correct posture is transparency, not certainty.
What to Track at Every Follow-Up
Instead of asking, "Which peptide fixes brain fog?" ask:
What changed, what can be measured, and what still needs to be ruled out?
That question produces better documentation and better patient conversations.
At each follow-up, record:
- The patient's original symptoms
- The intervention being evaluated
- Sleep changes
- Alcohol or substance changes
- Stress and work changes
- Exercise and movement changes
- Medication and supplement changes
- Relevant labs or diagnostic findings
- Patient-reported benefit
- Any adverse effects
This does not create a perfect experiment. Real patients are not laboratory conditions. But it gives you a clearer picture than simply asking whether the patient "feels better."
It also protects against a common clinical error: mistaking a compelling story for reliable evidence.
Who Needs a Full Cognitive Workup First
Anyone with new, worsening, sudden, or unexplained cognitive change should receive appropriate evaluation. Red flags may include significant confusion, personality changes, neurological symptoms, severe headaches, weakness, speech changes, or rapidly progressing symptoms.
Those patients need answers before experimentation.
No peptide should become a substitute for a proper workup.
The goal is not to dismiss every possible intervention. The goal is to avoid giving one intervention credit for a total life change.
The rooster may be standing in the yard when the sun comes up.
That does not mean it caused the sunrise.
Frequently Asked Questions
Are Semax, Selank, and Pinealon FDA approved?
No. None of these compounds should be presented as FDA-approved treatments for brain fog, focus, aging, anxiety, or cognitive decline. The FDA has specifically raised safety, characterization, and evidence concerns regarding Semax and Selank-related compounded substances [4, 7].
Does a patient feeling better prove that a peptide worked?
No. Improvement shows that the patient improved. It does not prove which variable caused the change. Sleep, stress, alcohol, exercise, medications, expectation, and natural symptom variation may all contribute.
Is there research on Semax and Selank?
Yes. Published studies exist, including animal research on Semax and clinical studies of Selank in anxiety-related conditions. However, the existence of research does not automatically establish broad clinical effectiveness, long-term safety, or FDA approval [3, 5, 6].
Should practitioners use these peptides for new cognitive symptoms?
New or worsening cognitive symptoms warrant appropriate evaluation before assuming a peptide is the answer. The priority is identifying potentially treatable causes and ruling out urgent conditions.
Why track sleep, alcohol, stress, and movement at follow-up?
Because they are major confounding variables. If they change at the same time as a peptide, you cannot accurately interpret the outcome unless you document them.
What should practitioners tell patients?
Be clear about what is known, what is uncertain, and what has not been established. Avoid disease-treatment claims, guaranteed outcomes, and language that implies a compound is proven when the evidence does not support that conclusion.
What are common causes of brain fog?
Many things can affect memory and thinking. The National Institute on Aging lists sleep problems, alcohol or drug misuse, medication side effects, stress, thyroid problems, and low vitamin B12 among the possible causes [10]. Check these before a peptide enters the conversation.
How strong is the evidence for Pinealon?
Limited. Most published Pinealon research comes from cell and animal studies, largely from one research group, and no Pinealon trial is registered on ClinicalTrials.gov [8, 9]. Present it with transparency, not certainty.
When does brain fog need a full cognitive workup?
When cognitive change is new, worsening, sudden, or unexplained. Red flags such as significant confusion, personality changes, speech changes, weakness, or rapidly progressing symptoms call for evaluation before any peptide discussion. The National Institute on Aging advises talking with a doctor about noticeable changes in memory [10].
References
- U.S. Food and Drug Administration. FDA 101: Dietary Supplements. Content current as of 06/02/2022. fda.gov
- U.S. Food and Drug Administration. Unapproved Drugs. Content current as of 05/09/2024. fda.gov
- Romanova GA, Silachev DN, Shakova FM, et al. Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex. Bull Exp Biol Med. 2006;142(6):663-666. doi:10.1007/s10517-006-0445-0. PMID 17603664
- U.S. Food and Drug Administration. July 24, 2026 FDA Presentations, Pharmacy Compounding Advisory Committee Meeting (Semax-Related Bulk Drug Substances). fda.gov/media/193774/download
- Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID 18454096
- Medvedev VE, Tereshchenko ON, Israelian AIu, et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22. PMID 25176261
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Content current as of April 22, 2026. fda.gov
- Khavinson V, Ribakova Y, Kulebiakin K, et al. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Res. 2011;14(5):535-541. doi:10.1089/rej.2011.1172. PMID 21978084
- ClinicalTrials.gov. Search results for "Pinealon": 0 studies (verified October 30, 2026). clinicaltrials.gov
- National Institute on Aging. Memory Problems, Forgetfulness, and Aging. Content reviewed November 22, 2023. nia.nih.gov